-
Cotation en bourse
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLire la suiteTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLire la suiteEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLire la suiteEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lire la suiteThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lire la suiteShaping capital markets for future generations
Curetis listing anniversary
11/11/2016
Curetis celebrates one year listed anniversary
Curetis (ticker symbol: CURE) celebrates its one-year listed anniversary at Euronext by sounding the gong. Oliver Schacht, CEO Curetis, visits Beursplein 5 and sounds the gong.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases.
Curetis is a molecular diagnostics company focusing on the detection of severe infectious disease in hospitalized patients. Its CE IVD marked Unyvero platform is marketed across Europe and has recently also successfully completed a US FDA trial for its LRT lower respiratory tract infection cartridge.
For more information: www.curetis.com